Financial Survey: MaxCyte (MXCT) and Its Rivals

MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare MaxCyte to related companies based on the strength of its profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and earnings.

Earnings & Valuation

This table compares MaxCyte and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MaxCyte	$33.89 million	-$19.08 million	-27.47
MaxCyte Competitors	$2.80 billion	$101.15 million	13.51

MaxCyte’s peers have higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares MaxCyte and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MaxCyte	-41.15%	-7.39%	-6.78%
MaxCyte Competitors	-260.35%	-8.17%	-2.92%

Analyst Ratings

This is a summary of current ratings and price targets for MaxCyte and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	0	0	5	0	3.00
MaxCyte Competitors	105	773	1306	30	2.57

As a group, “Commercial physical research” companies have a potential upside of 40.87%. Given MaxCyte’s peers higher possible upside, analysts plainly believe MaxCyte has less favorable growth aspects than its peers.

Insider and Institutional Ownership

65.9% of MaxCyte shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 5.4% of MaxCyte shares are owned by company insiders. Comparatively, 11.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MaxCyte peers beat MaxCyte on 7 of the 12 factors compared.

About MaxCyte (Get Rating)

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.